Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema

This is not the most recent version

Information

DOI:
https://doi.org/10.1002/14651858.CD007419.pub3Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 12 December 2012see what's new
Type:
  1. Intervention
Stage:
  1. Review
Cochrane Editorial Group:
  1. Cochrane Eyes and Vision Group

Copyright:
  1. Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Gianni Virgili

    Correspondence to: Department of Translational Surgery and Medicine, Eye Clinic, University of Florence, Florence, Italy

    [email protected]

  • Mariacristina Parravano

    Ophthalmology, Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmolologia‐IRCCS, Rome, Italy

  • Francesca Menchini

    Department of Ophthalmology, University of Udine, Azienda Ospedaliero‐universitaria di Udine, Udine, Italy

  • Massimo Brunetti

    Local Health Unit, Modena, Italy

Contributions of authors

Conceiving the review: MP, FM, GV
Designing the review: MP, FM, GV
Coordinating the review: MP
Data collection for the review
‐ Designing electronic search strategies: Cochrane Eyes and Vision Group editorial base
‐ Undertaking manual searches: MP, FM
‐ Screening search results: MP
‐ Organizing retrieval of papers: MP
‐ Screening retrieved papers against inclusion criteria: MP, FM, GV
‐ Appraising quality of papers: MP, FM, GV
‐ Extracting data from papers: MP, FM, GV
‐ Writing to authors of papers for additional information: MP, FM, GV
‐ Providing additional data about papers: MP, FM, GV
‐ Obtaining and screening data on unpublished studies: MP, FM, GV
Data management for the review
‐ Entering data into RevMan: MP, FM, GV
Analysis of data: MP, FM, GV
Interpretation of data
‐ Providing a methodological perspective: MP, FM, GV
‐ Providing a clinical perspective: MP, FM, GV
‐ Providing a policy perspective: MP, FM, GV
‐ Writing the review: MP, FM, GV
Providing general advice on the review: GV
Securing funding for the review: MP, FM, GV

Sources of support

Internal sources

  • Azienda Ospedaliero‐Universitaria Careggi & University of Florence, based on funding by the Tuscany Region, Italy.

External sources

  • No sources of support supplied

Declarations of interest

None known

Acknowledgements

The Cochrane Eyes and Vision Group (CEVG) created and executed the search strategies. We thank Maria Diener‐West, Catey Bunce and Paolo Lanzetta for their comments on the review and Anupa Shah for her assistance throughout the review process.

Wen Xing and Catey Bunce provided visual acuity data on BOLT study.

Dr. Oliver Zeitz and dr. Christopher James (Bayer HealthCare) provided additional data regarding DA VINCI.

Meagan Huggins provided clarification regarding randomisation process in DRCRnet.

Richard Wormald (Co‐ordinating Editor for CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.

Version history

Published

Title

Stage

Authors

Version

2023 Jun 27

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis

Review

Gianni Virgili, Katie Curran, Ersilia Lucenteforte, Tunde Peto, Mariacristina Parravano

https://doi.org/10.1002/14651858.CD007419.pub7

2018 Oct 16

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis

Review

Gianni Virgili, Mariacristina Parravano, Jennifer R Evans, Iris Gordon, Ersilia Lucenteforte

https://doi.org/10.1002/14651858.CD007419.pub6

2017 Jun 22

Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis

Review

Gianni Virgili, Mariacristina Parravano, Jennifer R Evans, Iris Gordon, Ersilia Lucenteforte

https://doi.org/10.1002/14651858.CD007419.pub5

2014 Oct 24

Anti‐vascular endothelial growth factor for diabetic macular oedema

Review

Gianni Virgili, Mariacristina Parravano, Francesca Menchini, Jennifer R Evans

https://doi.org/10.1002/14651858.CD007419.pub4

2012 Dec 12

Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema

Review

Gianni Virgili, Mariacristina Parravano, Francesca Menchini, Massimo Brunetti

https://doi.org/10.1002/14651858.CD007419.pub3

2009 Oct 07

Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema

Review

Mariacristina Parravano, Francesca Menchini, Gianni Virgili

https://doi.org/10.1002/14651858.CD007419.pub2

2009 Jul 08

Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema

Protocol

Mariacristina Parravano, Francesca Menchini

https://doi.org/10.1002/14651858.CD007419

Differences between protocol and review

Differences between protocol and review in the first published version of this review

We have added LILACS to the list of databases which have been searched for this review. We have used a sensitivity analysis for the robustness of results in comparisons including only one trial according to a statistical technique derived from a recent publication (Borm 2009).

Changes in update 2012 compared to the protocol of the previous version

  1. We have specified that studies comparing different anti‐VEGF drugs will also be included in this review, but intravitreal steroids will be excluded as they are the subject of another Cochrane Review. Moreover, we decided not to consider the comparison of bevacizumab with bevacizumab plus trimacinolone, which included two studies; in fact this comparison investigates the additional effect of triamcinolone rather than the benefit with anti‐VEGF drugs.

  2. We have computed indirect comparison odds ratios (OR) of gain of 3+ and 2+ lines for bevacizumab and pegaptanib versus ranibizumab as the reference drug using random‐effects logistic regression.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.